Status: Not yet recruiting
Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma
This study aims to evaluate the efficacy and safety of Rimegepant combined with AG chemotherapy as first-line treatment for metastatic pancreatic cancer.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Xiuchao WangUpdated: Mar 16, 2026
Eligibility criteria
The patient has good compliance, understands the study procedures, and has signe... [+16]
Patients with a history of other malignancies within the past 5 years, except fo... [+14]